Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor. (12th April 2023)

• Record Type: Journal Article
• Authors: Weich, Alexander; Serfling, Sebastian E.; Yi, Heqing; Buck, Andreas K.; Higuchi, Takahiro; Werner, Rudolf A.
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 4(2023)
• Page Start: 335
• Page End: 336
• Publication Date: 2023-04-12
• Subjects: complete remission -- NEN -- NET G2 -- neuroendocrine tumor -- pancreas -- peptide receptor radionuclide therapy -- PRRT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004537
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: We report the case of a 52-year-old man affected with a metastasized neuroendocrine tumor (G2) of the pancreas. After surgical removal, follow-up imaging 36 months later revealed somatostatin receptor–positive liver lesions. Because of disease progression under cold somatostatin analogs 6 months later, peptide receptor radionuclide therapy was performed, that induced complete remission (CR), supporting the notion that "hot" somatostatin analogs can achieve CR even in patients affected with pancreatic G2 neuroendocrine tumor. Of note, such cases exhibiting CR upon peptide receptor radionuclide therapy are extremely rare and further investigations may pool those exceptional treatment responders.